Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153489 | 0.85 | PTGDR2 (0.33) | — | |
| SCHEMBL2618031 | 0.85 | PTGDR2 (0.33) | — | |
| SCHEMBL19201307 | 0.85 | PTGDR2 (0.33) | — | |
| SCHEMBL18958958 | 0.84 | EPHX2 (0.36) | NPSR1 | |
| SCHEMBL13464242 | 0.83 | HTT (0.32) | — | |
| SCHEMBL18106103 | 0.83 | — | — | |
| SCHEMBL31650890 | 0.83 | PTGDR2 (0.30) | — | |
| SCHEMBL13228015 | 0.83 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL15077561 | 0.83 | — | — | |
| SCHEMBL26255921 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9599628-B2 | Small molecule-dependent split aptamer ligation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170015710-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160258970-A1 | SMALL MOLECULE-DEPENDENT SPLIT APTAMER LIGATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-09-08 | — | — | US | disclosed |
| US-9279805-B2 | Small molecule-dependent split aptamer ligation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150218220-A1 | AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | AGENSYS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150072352-A1 | SMALL MOLECULE-DEPENDENT SPLIT APTAMER LIGATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140256831-A1 | HYDROGEL AND METHOD FOR PRODUCING SAME | THE UNIVERSITY OF TOKYO (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256831-A1 | HYDROGEL AND METHOD FOR PRODUCING SAME | THE UNIVERSITY OF TOKYO (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8735367-B2 | Small molecule-dependent split aptamer ligation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130164739-A1 | SMALL MOLECULE-DEPENDENT SPLIT APTAMER LIGATION | UNIVERSITY OF UTAH | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015710-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | NPSR1 384/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | NPSR1 7/4885 |
| US-20140256831-A1 | HYDROGEL AND METHOD FOR PRODUCING SAME | CD44, CSGALNACT1, CDC37 | NPSR1 1672/4885 |
| US-20150218220-A1 | AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | NPSR1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.